Nabriva Therapeutics plc Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2020 to Q4 2022

Taxonomy & unit: us-gaap: USD
Description: Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary: Nabriva Therapeutics plc quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2020 to Q4 2022.
Nabriva Therapeutics plc Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending December 31, 2022 was $3.21M, a 63.5% decline year-over-year.

Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)

Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date	Report	Filed
Q4 2022	$3.21M	-$5.57M	-63.5%	Dec 31, 2022	10-K	2023-04-17
Q4 2021	$8.78M	+$8.72M	+15575%	Dec 31, 2021	10-K	2023-04-17
Q4 2020	$56K			Dec 31, 2020	10-K	2022-03-29

* An asterisk sign (*) next to the value indicates that the value is likely invalid.